EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDYLLTRA Compared to Chemotherapy Novel Treatment Option for Patients with Extensive-Stage Small Cell Lung Cancer That Has Progressed THOUSAND OAKS, Calif., June …
Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDYLLTRA Compared to Chemotherapy Novel Treatment Option for Patients with Extensive-Stage Small Cel… [+37212 chars]